You are here

iPSC-Derived Endothelial Cells to Treat Hemophilia

A recent STEM CELLS Translational Medicine article from the labs of Aijun Wang and Ping Zhou (University of California Davis, Sacramento, CA, USA) demonstrated that induced pluripotent stem cells (iPSCs) derived from hemophilia A patients can provide an ample supply of endothelial cells that can be genetically modified to produce functional factor VIII. Rose et al. describe how the stable engraftment of endothelial cells in neonatal and adult animals and the functional correction or alleviation of hemophilia A by these endothelial cells in animal models provide the basis for potential therapeutic development of corrected‐iPSC‐derived endothelial cells for the treatment of hemophilia A.